<?xml version='1.0' encoding='ISO-8859-1'?>
<xml>
<title>Illinois General Assembly - Bill Status for HB 2638         </title>
<shortdesc>OPIOID PRESCRIBER REQUIREMENTS</shortdesc>
<sponsor>
<sponsorhead1>House Sponsors</sponsorhead1><sponsors>Rep. Marcus C. Evans, Jr., Robyn Gabel, Katie Stuart and Michelle Mussman</sponsors>
</sponsor>
<lastaction>
<statusdate>1/13/2021</statusdate><chamber>House</chamber><action>Session Sine Die</action>
</lastaction>
<synopsis>
<synopsistitle></synopsistitle>
<reference>720 ILCS 570/315.7 new</reference><aliasreference></aliasreference><SynopsisText>     Amends the Illinois Controlled Substances Act. Provides that a prescriber shall offer a prescription for naloxone hydrochloride or another drug approved by the United States Food and Drug Administration for the complete or partial reversal of opioid depression to a patient when one or more of the following conditions are present: (1) the prescription dosage for the patient is 90 or more morphine milligram equivalents of an opioid medication per day; (2) an opioid medication is prescribed concurrently with a prescription for benzodiazepine; (3) the patient presents with an increased risk for overdose, including a patient with a history of overdose, a patient with a history of substance use disorder, or a patient at risk for returning to a high dose of opioid medication to which the patient is no longer tolerant. Provides other requirements and exemptions. Makes other changes. Effective January 1, 2020.</SynopsisText></synopsis>
<actions>
<statusdate>2/14/2019</statusdate><chamber>House</chamber><action>Filed with the Clerk by Rep. Marcus C. Evans, Jr.</action>
<statusdate>2/14/2019</statusdate><chamber>House</chamber><action>First Reading</action>
<statusdate>2/14/2019</statusdate><chamber>House</chamber><action>Referred to Rules Committee</action>
<statusdate>2/26/2019</statusdate><chamber>House</chamber><action>Assigned to Prescription Drug Affordability &amp; Accessibility Committee</action>
<statusdate>3/19/2019</statusdate><chamber>House</chamber><action>House Committee Amendment No. 1 Filed with Clerk by Rep. Marcus C. Evans, Jr.</action>
<statusdate>3/19/2019</statusdate><chamber>House</chamber><action>House Committee Amendment No. 1 Referred to Rules Committee</action>
<statusdate>3/19/2019</statusdate><chamber>House</chamber><action>Added Co-Sponsor Rep. Robyn Gabel</action>
<statusdate>3/20/2019</statusdate><chamber>House</chamber><action>House Committee Amendment No. 1 Rules Refers to Prescription Drug Affordability &amp; Accessibility Committee</action>
<statusdate>3/21/2019</statusdate><chamber>House</chamber><action>Added Co-Sponsor Rep. Katie Stuart</action>
<statusdate>3/28/2019</statusdate><chamber>House</chamber><action>Added Co-Sponsor Rep. Michelle Mussman</action>
<statusdate>3/29/2019</statusdate><chamber>House</chamber><action>Rule 19(a) / Re-referred to Rules Committee</action>
<statusdate>3/29/2019</statusdate><chamber>House</chamber><action>House Committee Amendment No. 1 Rule 19(c) / Re-referred to Rules Committee</action>
<statusdate>1/13/2021</statusdate><chamber>House</chamber><action>Session Sine Die</action>
</actions>
</xml>

